Expert Interview
A Second Look: Examining the potential of Merus' bispecific antibody, petosemtamab, in HNSCC with a focus on the data from the Phase 1/2 trial presented AACR 2023
Ticker(s): MRUSInstitution: MD Anderson
- Professor of Medicine Thoracic-Head & Neck Med Oncology at The University of Texas MD Anderson Cancer Center.
- Manages 20 patients with HNSCC per week.
- Research focused on defining the biological and molecular effects of the modulation of signal transduction pathways in lung, head and neck, and HPV+ cancers; has defined novel mechanisms of sensitivity and resistance to kinase inhibitors.
Can you please describe your clinical practice as it relates to HNSCC?
Added By: sara_adminWhat are your key take aways from the Phase 1/2 trial data of Merus' bispecific antibody, petosemtamab, presented at AACR 2023?
Added By: sara_adminPlease rate your level of excitement on a scale from 1 to 10 (10 being the most excited) about the potential of petosemtamab in patients with previously treated HNSCC?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
